Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Potential Impact of Oral Semaglutide on Coronary Artery Disease Progression Following Acute Coronary Syndrome: The POST-ACS Study

NCT05322200 is registered in ClinicalTrials.gov with Swansea Bay University Health Board as lead sponsor.

NCT NCT05322200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05322200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Potential Impact of Oral Semaglutide on Coronary Artery Disease Progression Following Acute Coronary Syndrome: The POST-ACS Study
Lead sponsor
Swansea Bay University Health Board
Phase
Phase 4
Overall status
Unknown status
Start date
August 31, 2022
Completion date
August 1, 2024
Enrollment
140 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, coronary artery disease, diabetes mellitus